US FDA accepts AstraZeneca and Mercks sNDA for Lynparza in combo with abiraterone and prednisone or prednisolone to treat patients with mCRPC

US FDA accepts AstraZeneca and Mercks sNDA for Lynparza in combo with abiraterone and prednisone or prednisolone to treat patients with mCRPC

By, Admin 17 August 2022

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that a supplemental New Drug Application (sNDA) for Lynparza in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date in the fourth quarter of 2022. In the US, prostate cancer is the second most common cancer in male patients. Approximately 10-20% of male patients with advanced prostate cancer are estimated to develop castration resistant prostate cancer (CRPC) within five years, and at least 84% of these men may develop metastases at the time of CRPC diagnosis. Patients with advanced prostate cancer have a particularly poor prognosis, and the five-year survival rate remains low. Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, said,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!